These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 24148970)

  • 1. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
    Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
    Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
    Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
    Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
    Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
    Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
    J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
    Shimizu K; Mizuno T; Shinga J; Asakura M; Kakimi K; Ishii Y; Masuda K; Maeda T; Sugahara H; Sato Y; Matsushita H; Nishida K; Hanada K; Dorrie J; Schaft N; Bickham K; Koike H; Ando T; Nagai R; Fujii S
    Cancer Res; 2013 Jan; 73(1):62-73. PubMed ID: 23108144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
    Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
    Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
    Nakamura T; Yamazaki D; Yamauchi J; Harashima H
    J Control Release; 2013 Oct; 171(2):216-24. PubMed ID: 23860186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
    Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
    Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
    Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
    Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
    Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
    Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
    Chung Y; Qin H; Kang CY; Kim S; Kwak LW; Dong C
    Blood; 2007 Sep; 110(6):2013-9. PubMed ID: 17581919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.